These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36353066)

  • 1. Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy.
    Marcq G; Evaristo G; Kool R; Shinde-Jadhav S; Skowronski R; Mansure JJ; Souhami L; Cury F; Brimo F; Kassouf W
    Eur Urol Open Sci; 2022 Sep; 43():14-21. PubMed ID: 36353066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Programmed Death Ligand-1 Expression on Tumor-Infiltrating Immune Cells in Patients Treated with Cisplatin-Based Combination Adjuvant Chemotherapy Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study.
    Lee DH; Jeong JY; Song W
    Onco Targets Ther; 2021; 14():845-855. PubMed ID: 33574678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
    Yan S; Zeng H; Jin K; Shao F; Liu Z; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Xu J
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35523436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy.
    Kool R; Marcq G; Shinde-Jadhav S; Mansure JJ; Saleh R; Rajan R; Aprikian A; Tanguay S; Cury FL; Brimo F; Souhami L; Kassouf W
    Eur Urol Open Sci; 2022 Feb; 36():26-33. PubMed ID: 35098169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
    Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases.
    Mao J; Yang C; Xin S; Cui K; Liu Z; Wang T; Hu Z; Wang S; Liu J; Song X; Song W
    Front Med (Lausanne); 2022; 9():949567. PubMed ID: 35979208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of the Ki67 index and programmed death-ligand 1 expression after radical cystectomy in patients with muscle-invasive bladder cancer.
    Horiguchi H; Hatakeyama S; Yoneyama T; Yoneyama MS; Tanaka T; Fujita N; Okamoto T; Yamamoto H; Yoneyama T; Yoshizawa T; Hashimoto Y; Kawaguchi T; Ohyama C
    Urol Oncol; 2021 Apr; 39(4):238.e9-238.e17. PubMed ID: 33308976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy.
    Hesswani C; Jackson CL; Marcq G; Hardy C; Kool R; Mansure JJ; Brimo F; Berman DM; Kassouf W
    Eur Urol Open Sci; 2023 Nov; 57():22-29. PubMed ID: 38020525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
    Anantharaman A; Friedlander T; Lu D; Krupa R; Premasekharan G; Hough J; Edwards M; Paz R; Lindquist K; Graf R; Jendrisak A; Louw J; Dugan L; Baird S; Wang Y; Dittamore R; Paris PL
    BMC Cancer; 2016 Sep; 16(1):744. PubMed ID: 27658492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors.
    Alessandrino F; Gujrathi R; Nassar AH; Alzaghal A; Ravi A; McGregor B; Sonpavde G; Shinagare AB
    Eur Urol Oncol; 2020 Oct; 3(5):680-686. PubMed ID: 31412003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death ligand-1 (PD-L1) immunohistochemical assessment using the QR1 clone in muscle-invasive urothelial carcinomas: a comparison with reference clones 22C3 and SP263.
    Loghin A; Nechifor-Boilă A; Borda A; Nechifor-Boilă IA; Voidazan S; Decaussin-Petrucci M
    Virchows Arch; 2022 Feb; 480(2):303-313. PubMed ID: 34669047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Expression of Programmed Death-Ligand 1 and Its Role in Differentiating Low-Grade and High-Grade Urothelial Carcinoma.
    Singh A; Kumari M; Haldar D; Kumari R; Ranjan N; Prasad R
    Cureus; 2024 Jun; 16(6):e62567. PubMed ID: 39027756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical Study of Bladder Cancer Molecular Subtypes and Their Association with PD-L1 Expression.
    Goutas D; Palamaris K; Stofas A; Politakis N; Despotidi A; Giannopoulou I; Goutas N; Vlachodimitropoulos D; Kavantzas N; Lazaris AC; Gakiopoulou H
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 expression in muscle invasive urothelial carcinoma: Comparison of SP142 and SP263 assay.
    Gupta G; Pasricha S; Kamboj M; Sharma A; Nayana NS; Durga G; Sharma A; Rawal S; Meh A
    Indian J Pathol Microbiol; 2022; 65(4):839-843. PubMed ID: 36308190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer.
    Liu ZH; Zheng FF; Mao YL; Ye LF; Bian J; Lai DH; Ye YL; Dai YP
    Oncol Lett; 2017 Jun; 13(6):4818-4824. PubMed ID: 28599483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
    Shirasawa M; Yoshida T; Shimoda Y; Takayanagi D; Shiraishi K; Kubo T; Mitani S; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Ichikawa H; Kohno T; Yamamoto N; Matsumoto S; Goto K; Watanabe SI; Ohe Y; Motoi N
    J Thorac Oncol; 2021 Dec; 16(12):2078-2090. PubMed ID: 34419685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer.
    Su X; Jin K; Guo Q; Xu Z; Liu Z; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Xu J
    Br J Cancer; 2024 Mar; 130(5):852-860. PubMed ID: 38212482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.